These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 7838659)

  • 21. [Toxic epidermal necrolysis in a patient treated with high doses of deflazacort].
    Navarro Llanos A; Elizalde Eguinoa J; Boto de los Bueys B; Pujol de la Llave E
    Med Clin (Barc); 1996 Apr; 106(15):599. PubMed ID: 8656765
    [No Abstract]   [Full Text] [Related]  

  • 22. [Problems in symptomatic therapy of rheumatic diseases with glucocorticoids and nonsteroidal antirheumatic agents].
    Mathies H
    Internist (Berl); 1979 Sep; 20(9):414-25. PubMed ID: 387649
    [No Abstract]   [Full Text] [Related]  

  • 23. Glucocorticoids.
    Kimberly RP
    Curr Opin Rheumatol; 1994 May; 6(3):273-80. PubMed ID: 8060761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with an anti-inflammatory drug is detrimental for muscle regeneration at Bothrops jararacussu envenoming: an experimental study.
    Vomero VU; Marques MJ; Neto HS
    Toxicon; 2009 Sep; 54(3):361-3. PubMed ID: 19375446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cutaneous adverse drug reactions to Fluticasone propionate and Deflazacort in an asthmatic patient.
    Ventura MT; Calogiuri GF; Buquicchio R; Di Leo E; Ferrannini A
    Contact Dermatitis; 2005 Aug; 53(2):118-9. PubMed ID: 16033410
    [No Abstract]   [Full Text] [Related]  

  • 26. [Epidemiology of corticosteroid-induced osteoporosis].
    Braun J
    Z Rheumatol; 2001 Apr; 60(2):107-10. PubMed ID: 11383044
    [No Abstract]   [Full Text] [Related]  

  • 27. [The limits of our therapeutical possibilities in rheumatic diseases (author's transl)].
    Trnavský K
    Cas Lek Cesk; 1978 Jul; 117(29-30):889-92. PubMed ID: 308392
    [No Abstract]   [Full Text] [Related]  

  • 28. Drug therapy of rheumatic diseases during pregnancy.
    Soscia PN; Zurier RB
    Bull Rheum Dis; 1992; 41(2):1-3. PubMed ID: 1600444
    [No Abstract]   [Full Text] [Related]  

  • 29. A national survey to assess investigation and management protocols followed in dealing with steroid-induced osteoporosis.
    Peshin R; Phelan M
    Clin Rheumatol; 2007 Sep; 26(9):1439-43. PubMed ID: 17235655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Adverse effects of antirheumatics in children and adolescents].
    Hoza J; Rubín A; Fink Z; Havelka S
    Cesk Pediatr; 1984 Sep; 39(9):536-9. PubMed ID: 6334566
    [No Abstract]   [Full Text] [Related]  

  • 31. Deflazacort in juvenile chronic arthritis.
    Loftus JK; Reeve J; Hesp R; David J; Ansell BM; Woo PM
    J Rheumatol Suppl; 1993 Apr; 37():40-2. PubMed ID: 8501751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transient osteoporosis of the hip: successful response to deflazacort.
    Carmona-Ortells L; Carvajal-Méndez I; García-Vadillo JA; Alvaro-Gracia JM; González-Alvaro I
    Clin Exp Rheumatol; 1995; 13(5):653-5. PubMed ID: 8575148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonsteroidal anti-inflammatory drugs (NSAID): use and misuse.
    Furst DE
    J Iowa Med Soc; 1983 May; 73(5):186-91. PubMed ID: 6602854
    [No Abstract]   [Full Text] [Related]  

  • 34. [Controlled clinical testing of a new anti-inflammatory agent].
    Malerba F; Barbi GL
    Clin Ter; 1969 Apr; 49(1):63-7. PubMed ID: 4930402
    [No Abstract]   [Full Text] [Related]  

  • 35. A comparative study of hydrocortisone versus deflazacort in drug-resistant epilepsy of childhood.
    Grosso S; Farnetani M; Mostardini R; Cordelli D; Berardi R; Balestri P
    Epilepsy Res; 2008 Sep; 81(1):80-5. PubMed ID: 18524542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Chronic respiratory failure and osteoporosis: a difficult problem to unravel].
    Orcel P
    Rev Mal Respir; 2001 Sep; 18(4 Pt 1):361-3. PubMed ID: 11547239
    [No Abstract]   [Full Text] [Related]  

  • 37. [Practice of the treatment with anti-inflammatory agents in rheumatology].
    Laurent F
    Therapeutique; 1970 May; 46():47-8. PubMed ID: 5310589
    [No Abstract]   [Full Text] [Related]  

  • 38. [Therapy of rheumatic disease using a new antirheumatic drug].
    Weigel H
    Z Allgemeinmed; 1974 Nov; 50(33):1527-31. PubMed ID: 4549149
    [No Abstract]   [Full Text] [Related]  

  • 39. [Bone metabolism in 53 children and adolescents with chronic inflammatory bowel disease].
    Scheer K; Kratzsch J; Deutscher J; Gelbrich G; Borte G; Kiess W
    Klin Padiatr; 2004; 216(2):62-6. PubMed ID: 15106075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacological properties and therapeutic effect of azapropazon in rheumatic diseases].
    Fiegel G
    Z Allgemeinmed; 1973 Apr; 49(12):592-4. PubMed ID: 4576254
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.